It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Phototherapy converts lipophilic unconjugated bilirubin to hydrophilic bilirubin photoisomers, such as lumirubin. We comparatively used a blue light-emitting diode (LED) and a green fluorescent lamp (FL) as light sources for phototherapy of hyperbilirubinemic preterm neonates with the aim of examining potential differences in urinary lumirubin excretion between these two wavelengths. Urinary lumirubin levels were measured using a fluorescence assay with blue light exposure in the presence of the unconjugated bilirubin-inducible fluorescent protein UnaG, and denoted as urinary UnaG-bound bilirubin (UUB)/creatinine (Cr) (μg/mg Cr). Preterm neonates born at ≤ 33 weeks gestational age and treated with phototherapy were subjected to this study. The maximum UUB/Cr level during phototherapy per device intensity was compared between neonates treated with the blue LED and the green FL. A total of 61 neonates were examined to determine the maximum UUB/Cr levels. The median of maximum UUB/Cr excretion per light intensity of each device (μg/mg Cr/μW/cm2/nm) was 0.83 for the blue LED and 1.29 for the green FL (p = 0.01). Green light was found to be more effective than blue one for bilirubin excretion via urinary lumirubin excretion. This is the first spectroscopic study to compare the efficacy of phototherapy at different wavelengths using fluorescence assay.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nara Medical University Hospital, Division of Neonatal Intensive Care, Maternal, Fetal and Neonatal Medical Center, Kashihara-City, Japan (GRID:grid.474851.b) (ISNI:0000 0004 1773 1360)
2 Nara Medical University Hospital, Central Clinical Laboratory, Kashihara-City, Japan (GRID:grid.474851.b) (ISNI:0000 0004 1773 1360)
3 Ushio Inc, R&D Division, Himeji-City, Japan (GRID:grid.471270.7) (ISNI:0000 0004 1808 0424); SANKEN, Osaka University, Ibaraki-City, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
4 Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, Wako-City, Japan (GRID:grid.474690.8); Biotechnological Optics Research Team, RIKEN Center for Advanced Photonics, Wako-City, Japan (GRID:grid.509457.a) (ISNI:0000 0004 4904 6560)
5 Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, Wako-City, Japan (GRID:grid.474690.8)